Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of Widespread Eosinophilic Cellulitis (Wells' Syndrome) with Benralizumab.

Literature DB >> 33205827

Treatment of Widespread Eosinophilic Cellulitis (Wells' Syndrome) with Benralizumab.

Maria Blomberg¹, Charlotte Winther, Svetlana Høyrup, Lone Skov.

Abstract

Entities: Chemical

Keywords: antibodies; asthma; benralizumab; eosinophilic cellulitis; humanized; monoclonal; Wells syndrome

Mesh：

Substances：

Year: 2020 PMID： 33205827 PMCID： PMC9309837 DOI： 10.2340/00015555-3697

Source DB: PubMed Journal: Acta Derm Venereol ISSN： 0001-5555 Impact factor: 3.875

Keyword Cloud
References

× No keyword cloud information.

7 in total

Review 1. Treatment of eosinophilic cellulitis (Wells syndrome) - a systematic review.

Authors: F Räßler; J Lukács; P Elsner
Journal: J Eur Acad Dermatol Venereol Date: 2016-06-29 Impact factor: 6.166

2. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β₂-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.

Authors: Eugene R Bleecker; J Mark FitzGerald; Pascal Chanez; Alberto Papi; Steven F Weinstein; Peter Barker; Stephanie Sproule; Geoffrey Gilmartin; Magnus Aurivillius; Viktoria Werkström; Mitchell Goldman
Journal: Lancet Date: 2016-09-05 Impact factor: 79.321

3. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.

Authors: William W Busse; Eugene R Bleecker; J Mark FitzGerald; Gary T Ferguson; Peter Barker; Stephanie Sproule; Richard F Olsson; Ubaldo J Martin; Mitchell Goldman
Journal: Lancet Respir Med Date: 2018-11-08 Impact factor: 30.700

Treatment of Widespread Eosinophilic Cellulitis (Wells' Syndrome) with Benralizumab.

Review 1. Treatment of eosinophilic cellulitis (Wells syndrome) - a systematic review.

2. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β₂-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.

3. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.

4. Wells syndrome in adults and children: a report of 19 cases.

Review 5. Eosinophilic Dermatoses: Recognition and Management.

6. Wells syndrome and its relationship to Churg-Strauss syndrome.

7. Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab.

Treatment of Widespread Eosinophilic Cellulitis (Wells' Syndrome) with Benralizumab.

Review 1. Treatment of eosinophilic cellulitis (Wells syndrome) - a systematic review.

2. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.

3. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.

4. Wells syndrome in adults and children: a report of 19 cases.

Review 5. Eosinophilic Dermatoses: Recognition and Management.

6. Wells syndrome and its relationship to Churg-Strauss syndrome.

7. Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab.

2. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β₂-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.